已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparison of outcomes between surgery and chemoradiotherapy after endoscopic resection for pT1a-MM with lymphovascular invasion or pT1b esophageal squamous cell carcinoma: Japanese multicenter propensity score-matched study

医学 淋巴血管侵犯 外科肿瘤学 危险系数 内科学 放化疗 食管鳞状细胞癌 倾向得分匹配 肿瘤科 腹部外科 食管癌 回顾性队列研究 比例危险模型 外科 胃肠病学 癌症 置信区间 转移
作者
Yoshinobu Yamamoto,Ryu Ishihara,Hirofumi Kawakubo,M. Nishikawa,Sachiko Yamamoto,Tomohiro Kadota,Seiichiro Abe,Masao Yoshida,Tsutomu Tanaka,Hiroaki Nagano,Hiroyoshi Nakanishi,Tetsuya Yoshizaki,Kotaro Waki,Akiko Takahashi,Yoshiyasu Kitagawa,Ken‐ichi Mizuno,Kenro Kawada,Yoshiyasu Kono,Chikatoshi Katada,Takashi Hashimoto,Yasuaki Nagami,Toshiyuki Yoshio,Toshio Shimokawa,Keiji Nihei,Kazuo Koyanagi,Ken Kato,Tomonori Yano,Manabu Muto,Yuko Kitagawa
出处
期刊:Journal of Gastroenterology [Springer Science+Business Media]
标识
DOI:10.1007/s00535-024-02188-7
摘要

Abstract Background Lymphovascular invasion (LVI) or pT1b is noncurative after endoscopic resection (ER) for esophageal squamous cell carcinoma (ESCC), and therefore surgery or chemoradiotherapy (CRT) is recommended. However, there has been debate regarding which treatment has better outcomes and whether individual risks should be considered. Methods This was a multicenter, retrospective study conducted at 65 hospitals in Japan. The inclusion criteria were patients with ESCC who underwent ER between January 2006 and December 2015, with pT1a-muscularis mucosa (MM) with LVI or pT1b, with negative vertical margins, cN0M0, and who underwent surgery or CRT. A 1:1 propensity score-matched analysis was performed between two groups. The primary and secondary end points were overall survival (OS) and relapse-free survival (RFS). OS and RFS were also compared between two subgroups: low risk (pT1a-MM with LVI and pT1b without LVI) and high risk (pT1b with LVI) for metastatic recurrence. Results Among 472 patients, 160 patients were selected from each group. The OS and RFS did not differ between surgery and CRT groups (hazard ratio, 0.887; P = .635 and hazard ratio, 1.036; P = .876, respectively). Subgroup analysis showed that CRT had a better prognosis in the low-risk group, and conversely, surgery had a better prognosis in the high-risk group. But these were not significant. The high-risk CRT group had a significant worse prognosis than the low-risk CRT group. Conclusions In patients with noncurative ER for ESCC, surgery and CRT showed no difference in long-term outcomes. Indications for CRT in the high-risk group need further investigation because of poor prognosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Leo发布了新的文献求助10
1秒前
竹攸完成签到 ,获得积分20
2秒前
日尧完成签到,获得积分10
3秒前
358489228完成签到,获得积分10
3秒前
yummm完成签到 ,获得积分10
5秒前
徐伟业完成签到 ,获得积分10
5秒前
Owen应助LLL采纳,获得10
7秒前
共享精神应助湿地小怪兽采纳,获得10
7秒前
圆月弯刀完成签到 ,获得积分10
7秒前
科研通AI6.2应助Aqua采纳,获得10
8秒前
豆豆完成签到,获得积分10
12秒前
Owen应助我爱山之东采纳,获得10
12秒前
辣椒油完成签到,获得积分10
13秒前
666完成签到 ,获得积分10
14秒前
自觉的猕猴桃完成签到,获得积分10
14秒前
欢呼宛秋完成签到,获得积分10
16秒前
24秒前
酷波er应助深情的热狗采纳,获得10
24秒前
晴文发布了新的文献求助30
26秒前
女爰舍予完成签到 ,获得积分10
27秒前
yili应助LIU采纳,获得10
28秒前
29秒前
飞快的书南完成签到 ,获得积分10
29秒前
科研通AI6.4应助小苍小苍采纳,获得10
34秒前
35秒前
月下荷花完成签到 ,获得积分10
38秒前
中科院一区选手完成签到,获得积分10
38秒前
DPH完成签到 ,获得积分10
40秒前
40秒前
随机科研完成签到,获得积分10
42秒前
raffinose发布了新的文献求助10
42秒前
晴文完成签到,获得积分10
44秒前
jane123完成签到,获得积分10
46秒前
星辰大海应助sun采纳,获得10
47秒前
我真是坠了完成签到,获得积分10
48秒前
巨型肥猫完成签到 ,获得积分10
49秒前
52秒前
战斗吧少女完成签到 ,获得积分10
54秒前
汪鸡毛完成签到 ,获得积分0
55秒前
57秒前
高分求助中
Markov Chain Monte Carlo 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Bend stiffness of submarine cables – an experimental and numerical investigation 5000
Advanced Weaponeering Fourth Edition, Volume 2 1000
Weaponeering: An Introduction Fourth Edition, Volume 1 1000
悉尼大学博士学位论文,题目:Modelling and testing of one-sided stitched laminated composites. 作者:Kristopher P. Plain 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7542789
求助须知:如何正确求助?哪些是违规求助? 9126701
关于积分的说明 19498924
捐赠科研通 7138734
什么是DOI,文献DOI怎么找? 3258475
关于科研通互助平台的介绍 2425826
邀请新用户注册赠送积分活动 2246617